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Abstract
Radiation exposures, both intentional and unintentional, have influence on 
normal tissue function. Short-term and long-term injuries can occur to all cell 
systems of both limited and rapid self-renewal potential. Radiation effects can last 
a lifetime for a patient and can produce complications for all organs and systems. 
Often invisible at the time of exposure, the fingerprints for cell damage can appear 
at any timepoint after. Health-care providers will need comprehensive knowledge 
and understanding of the acute and late effects of radiation exposure and how these 
interrelate with immediate and long-term care.
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1. Introduction
Radiation exposure can occur during diagnosis and primary treatment of a 
cancer or during a nuclear incident. These exposures increase our need to educate 
health-care providers and first responders on assessing and managing patients 
[1–8]. Although effects on tissue may not be meaningful from a clinical perspec-
tive during an evaluation for healthcare, identification of radiation exposure from 
a dose and volume perspective is an important piece in the patient’s past medical 
history. Invisible fingerprints relevant to medical situations can declare themselves 
decades after exposure in spite of careful periodic evaluation. The dose and volume 
of the intentional exposure is usually well documented in the radiation therapy 
treatment record. Shadow parallel radiation records that are not entered into 
electronic health system records may not be available at the time of a related health-
care evaluation, and important clinical information may be too brief or inadequate. 
Many current electronic medical records (EMR) do not have a module for radiation 
oncology. Data acquisition and management of radiation oncology are conducted 
with proprietary software systems and are not directly included in the modern elec-
tronic record. Interfaces can be built to move small portions of records to the EMR; 
however these are not reliable modes of data transfer and, if transferred, often can-
not be easily retrieved when needed in the acute care setting. Unintentional expo-
sure including exposure from diagnostic imaging is more challenging to document 
as it is provider-dependent and limited reliable information is documented during a 
radiology procedure. Radiation dose exposure is estimated using distance and dura-
tion models from the primary source as victims, unlike health-care providers, are 
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frequently unmonitored [1–4, 6, 8]. While these estimation models may be useful, 
accuracy can be compromised, particularly in calculating the integral or total body 
dose as there are often multiple sources of radiation at the time of the unintended 
exposure along with thermal injury. With the increasing rate of cancer survivors 
and the transition of pediatric patients to adult care systems, there is a multilevel 
knowledge gap of the toxicities caused by radiation exposure and how the acute and 
late effects relate to patient care.
2. Radiation toxicity
2.1 Normal tissue damage
We arbitrarily categorize radiation injury into phases: acute injury (3 months 
from exposure), subacute (from 3 to 24 months from exposure), and late or chronic 
(>24 months from exposure). There is considerable overlap in these definitions, 
and acute injury can be less and non-predictive of chronic injury [1–4]. Acute 
intentional injuries, both expected and unanticipated, related to radiation therapy 
management of cancer are best managed by the responsible treating physicians 
during radiation treatment. These professionals are cognizant of the intended target 
and normal tissues in the treatment field. Their knowledge of radiation treatment’s 
impact on normal tissue is coupled with established and less well-established toxici-
ties with various applications of chemotherapy and targeted therapy. Unintentional 
radiation exposure requires additional support and evaluation by emergency ser-
vices working together with radiation safety experts, who are trained in managing 
radiation effects and assessing the dose received by the victims using models of time 
and distance from the epicenter of the event. This also includes evaluating the risk 
to caregivers of the victim if radioactive particles/elements remain on or in the vic-
tim. The acute phase of injury can affect many cell systems. This includes toxicity to 
limited and rapid self-renewal potential tissues such as the central nervous system, 
bone marrow, skin, and mucosal surfaces lining the head/neck and gastrointestinal 
system. Death can occur soon after exposure if it is not recognized in a timely man-
ner and appropriate support is not provided. Although injury to reticulum systems 
is less common from radiation exposure due to limited self-renewal of these cell 
systems, injury to these systems including thermal injury eliminate the scaffolding 
needed for structural repair of cell systems with rapid self-renewal potential as 
disorderly repair can severely limit cell function.
From an individual cellular perspective, radiation therapy has direct impact 
on intracellular molecules and can cause both single-strand and double-strand 
DNA breaks which are repaired through multiple mechanisms. Because water is 
an important intracellular compound, oxygen compounds including free radi-
cal formation creates injury to cells through ionization from radiation exposure. 
These processes are important for cells and groups of cells near each other. The 
significance of the injury is directly related to the volume of tissue injured from the 
exposure as well as the degree of injury to support cells (stroma) that often have a 
more limited self-renewal capacity. If stroma is significantly damaged, cells with 
rapid self-renewal potential will not have a support architecture to reorganize and 
maintain function. The seriousness of acute and late injury is also proportional to 
the dose and volume of tissue exposed. Late injury is manifested by accelerated 
fibrosis coupled with limited blood vessel proliferation. The mechanism of late 
injury is multifactorial in origin including damage to rapid and limited self-renewal 
potential tissues, blood vessels, and intrinsic repair capacity of the cell system 
injured mitigated by mechanisms that accelerate fibrosis including TGF beta [9].
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Radiation exposure symptoms differ with the severity of the exposure. At very 
high single-fraction total body doses (>10 Gy (Gray)), near-immediate death will 
occur through cerebrovascular syndrome despite medical care. The syndrome is 
due to profound edema within the brain and meninges associated with collapse of 
all neuromuscular processes due to swelling and herniation of the brain through the 
foramen magnum. At total body doses of 5–12 Gy, death without support will occur 
within a few weeks as a result of profound fluid loss and diarrhea due to denudation 
and destruction of the gastrointestinal system. This can affect both stem cells and 
cause secondary injury to subdermal structures deforming the architecture of the 
bowel inhibiting absorption and promoting fluid loss. Patient survival is directly 
correlated with gastrointestinal (fluid/nutrition) and bone marrow (blood/blood 
product) support during this phase after exposure. A single total body dose of 10 Gy 
will eradicate a large segment of the stem cells within the gastrointestinal crypts. 
Although this dose does not directly affect differentiated adult cells, the exposure 
eliminates the stem cell self-renewal potential; therefore, the gastrointestinal tract 
mucosal surface becomes denuded, and the reticulum architecture supporting cell 
organization can be damaged. As a result, with no barrier for fluid and blood loss, 
clinical deterioration will occur often within days. At total body exposure doses of 
2–5 Gy, death occurs from destruction to the hematopoietic system with primary 
damage to both stem cells and cells of established lineation. Cells cannot sustain 
self-renewal, and clinical deterioration can occur with primary marrow failure and 
secondary infection. Lymphocytes may die an intermitotic death; thus the degree of 
lymphopenia can provide indirect assessment of dose from exposure [1, 5–8].
During exposure, symptoms consistent with a radiation syndrome will be 
developed by the victim and can be seen as early as 15 minutes from the initial 
exposure [1, 6, 8]. Symptom severity is proportional to dose. At higher doses, 
victims can experience severe gastrointestinal fluid loss, secondary fever from 
exposure to homeopathic pathogens, and hypotension due to fluid loss suggesting 
significant toxicity. Often identified at lower dose exposure, the prodromal phase 
is followed by a latent interval during which the person may look and feel clini-
cally well for days to weeks. After this gastrointestinal and hematopoietic damage 
may become visible and require intervention to prevent further acute clinical 
deterioration [1, 5–8].
If the total body exposure is <4–5 Gy, most experts currently recommend no 
immediate intervention other than symptomatic treatment with fluids and blood 
support. This would include periodic hydration and antiemetic therapy for nausea 
and vomiting. As needed, infection can be treated with antibiotics. Death associ-
ated with the hematopoietic syndrome becomes a real concern for exposure >5 Gy. 
Barrier nursing intervention and appropriate blood product support may improve 
survival. Experience from recent nuclear events suggest that efforts to limit bleed-
ing, infection, and physical trauma during the blood count nadir may improve the 
LD 50/30 (50% survival at 30 days) to and possibly beyond 7 Gy.
Dermal surfaces can receive much higher doses than internal organs, particu-
larly if the exposure is related to particles. Dermal injuries can be primitive dose 
biomarkers with epilation/erythema at 3–6 Gy and wet desquamation, bullae, 
ulceration, and necrosis visible at increased doses [1, 10]. However, if the exposure 
is a contaminate of radioactive particle and photon exposure, dermal dose may not 
be an accurate assessment of total body dose. Dermal injuries can be life-threat-
ening due to concurrent infection. Injuries should be managed with the same care 
offered to burn victims with care taken to monitor health-care staff in case there are 
residual particles which can transmit unintentional dose to health-care providers. 
Residual exposure can be identified with careful monitoring with dosimeters as 
done in brachytherapy treatments for health-care providers.
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An accurate assessment of dose is very important during the triage and care of 
victims with unintended exposure. Health-care workers are often monitored with 
dosimeters; however, the public will not have access to these tools. Therefore, radia-
tion exposure and dose assessment experts are important early in the evaluation 
including analysis of the population at risk. As radiation dose increases, the time to 
emesis decreases, and rapid onset of nausea and vomiting suggests higher exposure. 
As indicated, a decline in lymphocyte count or abnormal lymphocyte cytogenetics 
can be an indirect estimate of dose within 1–2 days of exposure. [1, 6–8, 11]. The 
Radiation Emergency Assistance Center for the United States (US) Department 
of Energy is operated by Oak Ridge Institute for Science and Education. Medical 
and radiation safety support is available through a 24-hour consultation service. 
Resources include radiation dose assessment in laboratory facilities and computation 
of dose from radionucleotide expertise. The 24-hour emergency telephone number is 
865.576.3131, and the website is https://orise.orau.gov/reacts/resources/index.html.
Recognized as an important clinical endeavor since nuclear weapons have 
been developed, there is keen interest in finding the chemical compounds that 
can protect normal tissues against radiation injury. Radiation protectors are com-
pounds applied or administered prior to exposure or in selected circumstances soon 
thereafter, to limit the impact and subsequent damage from exposure upon normal 
tissue. Compounds that can influence and promote the health of normal tissue 
after exposure are referred to as radiation mitigators. These therapeutic compounds 
are applied once the injury has occurred. Sulfhydryl compounds (SHs) have been 
shown to be effective radioprotectors. The simplest of these compounds, cysteine, 
contains a natural amino acid [11, 12]. The mechanism is thought to be related to the 
augmentation of amino acids in generating repair proteins at a higher level. Once 
the compound becomes intracellular, it loses the phosphate group and is thought to 
also serve as a free radical scavenger limiting intracellular damage.
Amifostine (ethyol) has been used to prevent xerostomia in patients receiving 
radiation therapy for head and neck cancer [13]. Several clinical trials have used 
amifostine to evaluate the effectiveness in protecting multiple mucosal surfaces 
as well as protecting pulmonary injury in patients undergoing total body irradia-
tion therapy as part of bone marrow transplant [13]. Amifostine was associated 
with improvement in patient assessment of mouth dryness and swallowing in a 
trial managed by the National Clinical Trial Network [13, 14]. The intrinsic fear 
of applying radiation protectors and mitigators in cancer therapy is the possible 
simultaneous tumor protective effect of these compounds in situ potentially limit-
ing the usefulness of the compounds. In this trial, it is important to note there was 
no difference in tumor control between patients receiving amifostine and patients 
receiving placebo. Nitroxides have been identified by Citrin and colleagues [11] as 
radioprotection agents in clinical development. Stable nitroxide free radicals and 
their specific electron reduction products, hydroxylamines, protect cells when 
exposed to oxidative stress. Accordingly, similar compounds are under review and 
evaluation. Antioxidants, such as alpha-tocopherol and beta-carotene, are under 
review for clinical application but to date have not been shown to be of clinical 
benefit [15, 16]. Investigators explored using gene therapy vectors with superoxide 
dismutase (SOD) to improve the intracellular component of SOD. The purpose is 
to limit damage caused by superoxide radicals. Investigators have demonstrated 
improved normal tissue tolerance to multiple organs including the esophagus with 
this approach [17, 18]. Captopril is a sulfhydryl containing analog of proline and 
inhibits angiotensin-converting enzyme and limits vasoconstriction. In animal 
models, it has been shown to benefit renal and pulmonary function with total body 
irradiation by limiting endothelial dysfunction, fluid exudation, and the subse-
quent development of pulmonary fibrosis. It also appeared to improve recovery 
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of hematoprogenitor cells [19–21]. ON 01210 (chlorobenzylsulfone derivative) is 
a small molecule kinase inhibitor which potentiates recovery of peripheral blood 
elements when administered before radiation. This may be of benefit to the general 
public and first responders in an unanticipated event if received early postexposure 
[22]. Animal models have shown a positive repopulation effect of gastrointestinal 
stem cells with R-spondin 1, a 263 amino acid protein [23]. CBLB502 is an agent 
that binds to toll-like receptor 5 (TLR5) activating NF-kB signal pathways. It is 
derived from the flagellin protein of Salmonella bacteria. It promotes recovery and 
regeneration of multiple organ system stem cells after TBI therapy including GI, 
oral mucosa, skin, and bone marrow progenitors. IL-6 and other bone marrow-
associated colony-stimulating factors likewise appear to work in parallel with this 
compound. The compound has a potential role as both a protectant and a mitigator 
[24]. Gamma-tocotrienol is an isomer of vitamin E and supports survival in animal 
models during total body irradiation in part by promoting bone marrow colony-
stimulating factors and IL-6. It also may play a role in upregulating anti-apoptotic 
gene expression after radiation [25, 26].
The role of mitigators is to limit injury from radiation exposure prior to the 
clinical manifestations of acute and late toxicities of the exposure and treatment. 
These compounds are generally thought to influence metabolic events occurring 
after exposure and limit radiation-associated damage. To date, cytokines and 
growth factors directed to stimulate stem cell proliferation are the most common 
tools used for this purpose. In clinical practice, these are commonly used to balance 
the inhibition of stem cell growth induced by chemotherapy and radiation to the 
hematopoietic, dermal, and gastrointestinal systems. These include granulocyte 
colony-stimulating factor (G-CSF) and keratinocyte growth factor (KGF) [27]. 
The factors contribute to many aspects of cell recovery. KGF has positive influence 
in the recovery of mucosal surfaces during the acute phase of toxicity as well as 
limits the late effects of radiotherapy, including xerostomia [11]. This is thought 
to potentially be of benefit to patients undergoing primary management for head 
and neck tumors. Mitigators of late toxicity are largely directed to limit fibrosis, 
which is thought to be a primary factor in late pulmonary injury and other tissues of 
more limited self-renewal potential [11, 15–18, 28–32]. Transforming growth factor 
beta (TGF-B) is the primary target to limit fibrosis [33–35]. Several compounds in 
development prevent late effects to either directly or indirectly target the TGF-B 
signaling pathway [33–35]. Tumor protection remains a concern when evaluating 
treatments associated with this parallel pathway for patients being treated for a 
malignancy, identical to compounds associated with radiation protection. There 
has been increasing interest in the use of stem cell therapy to repair both acute and 
chronic injuries. Mesenchymal stem cells modified with extracellular superoxide 
dismutase have been shown to improve survival of irradiated mice [36]. There is 
evidence these progenitors have a pleuripotent role and can be called upon by organ 
systems for differentiation along multiple pathways. Bone marrow stromal cells and 
myeloid progenitors are also under evaluation to mitigate radiation response. The 
survival benefit in mice with infusion of myeloid progenitors could be seen days 
after exposure [37–40]. The role of these infusional therapies in this circumstance 
remains to be optimally defined. The role of transplant and stem cell infusion dur-
ing the Chernobyl crisis was uncertain; however these techniques have improved 
and remain to be optimized in similar situations moving forward.
Neutrophil inhibition has the potential of limiting the severity of response 
to injury, and this has been evaluated in a series of experiments determining the 
potential role of these strategic compounds applied after radiation exposure. 
Experiments evaluated interleukin-1 alpha (IL-1α) as a mitigator of dermal dam-
age after radiation exposure. Interleukin-1 (IL-1) inhibits neutrophil infiltration 
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into the initial inflammatory response to injury. Assuming the initial inflamma-
tory phase can be titrated, short-term and long-term injuries could be influenced. 
Knockout mice deficient in IL-1α or the IL-1 receptor demonstrated both decreased 
dermal injury and more rapid healing after superficial radiation exposure with both 
electrons and a strontium applicator. This demonstrated the potential importance 
of this cytokine in generating and ameliorating radiation-associated skin damage 
associated with neutrophil inhibition. In a separate group of experiments, investi-
gators demonstrated that hyperspectral optical imaging (HSI) can reveal acute and 
late oxygenation and perfusion changes in dermal tissue with changes occurring as 
early as 12 hours after radiation exposure [41, 42]. Imaging changes in oxygenation 
and perfusion were seen within 12 hours of exposure and predated clinical vis-
ible skin change by 14 days [42]. Data sets from this group as part of an approved 
Institutional Review Board clinical trial for breast cancer patients receiving radia-
tion therapy have shown that changes in imaging correlate well with radiation dose 
and dose asymmetry in the treated volume. Areas of increased dose associated with 
patient topography, and chest wall separation demonstrated changes consistent 
with increased dose and daily fractionation.
In response to the need of developing compounds for radioprotection and 
mitigation, the Radiation Research Program of the National Cancer Institute in 
collaboration with the Small Business Innovation Research program has funded 
a series of contracts since 2010 to support the development of radiomodulators. 
To date, five of the funded applications have successfully transitioned to phase II 
funding. Eight clinical trials have been developed to establish safety and efficacy. 
Two drugs on trial are under evaluation as radioprotectors, and two are also being 
evaluated for anticancer properties. The sites of interest being studied include CNS 
injury, mucositis, proctitis/enteritis, bone marrow failure, and lung injury [43].
3. Conclusions
Researchers are developing a targeted pharmacologic response to protect and 
mitigate issues surrounding intentional and unintentional radiation exposure. 
A knowledge of normal tissue response to radiation injury will be important for 
all health-care providers moving forward. Radiation therapy patients, accident 
victims, and first responders will benefit from the growing body of knowledge.
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